Medicenna Therapeutics Corp (MDNAF)

$0.64 -0.03 (-4.50%)
Market Cap 55.47M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 71,600
Avg Vol 126,114
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 4%
Beta 1.84
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
AuriniaBeach
AuriniaBeach Jan. 29 at 9:00 PM
$MDNAF New PRISM-11 post, announcing that David has entered into a professional licensing and collaboration agreement with Medicenna Therapeutics. https://davidbakke.substack.com/p/a-note-on-prism-11-medicenna-and
1 · Reply
Lytnup
Lytnup Jan. 25 at 6:14 PM
$MDNAF Sorry if it’s been posted already - but latest corporate presentation deck for January 2026 is uploaded @ the company website. 50 pages - some kind of record!!! https://ir.medicenna.com/static-files/c4bd4892-7ceb-4d59-b061-77ea834ec278
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jan. 24 at 7:42 PM
$MDNAF For what it’s worth, Zack’s yesterday changed their rating…from a hold rating to a strong-buy rating
2 · Reply
BigJon123
BigJon123 Jan. 22 at 10:36 PM
$MDNAF maybe someone knows something we don’t! Good news on the way?
0 · Reply
Vikingess
Vikingess Jan. 22 at 6:55 PM
$MDNAF What did I miss?
0 · Reply
Dipper2013
Dipper2013 Jan. 22 at 4:50 PM
$MDNAF I think we need bad news to get it to go up...🤣
0 · Reply
Biosectors
Biosectors Jan. 20 at 11:39 PM
$MDNAF Let’s hope some movement in volume and price next week up to conference week. Praying a buy out indication before or after the conference presentation. Take a look at OCUL data due soon a buy out candidate right now 11 plus I am expecting 28 to 35 range offer. Similarly URGN it went to 30 but back to 20 now and a good shot of a buy out 35 to 45 range but no timeline it’s derisked asset generating revenue. SLS another candidate with potential CHRS another one still struggling but expect to be bought out in 2027
0 · Reply
Witzorwitzout1
Witzorwitzout1 Jan. 16 at 11:29 PM
$MDNAF Medicenna (US OTC: MDNAF | CAD: MDNA) long update Medicenna released their 2026 outlook yesterday morning and I want to highlight something important: MDNA11 doesn’t need Keytruda to work. The headline numbers, 50% objective response rate in expansion cohorts, 42% in patients who already failed checkpoint inhibitors, those are monotherapy results. No Keytruda. No Opdivo. Just MDNA11 alone. Think about that. These are patients who tried the blockbuster immunotherapies and they stopped working. MDNA11 is rescuing responses where checkpoints have failed. That’s a big deal. Why this matters for the investment thesis: There are now multiple paths to value here. 1.Monotherapy salvage: Patient fails Keytruda, give MDNA11 alone. This is the registrational path they’re planning for melanoma. 2.Combination play Pair MDNA11 with Keytruda upfront to expand the responder population from ~30% to potentially 40-50%. 3.Neoadjuvant (NEO-CYT) MDNA11 + checkpoint before surgery in earlier-stage melanoma.
1 · Reply
BigJon123
BigJon123 Jan. 16 at 6:52 PM
$MDNAF i bought more before these presentations came out - there is too much potential here IMO. The biggest hurdle (and a major one) is the funding for their plans but I am hopeful that FM can rub big pharma the right way. Interestingly, they’ve dropped the MDNA55 title and have reverted back to bizaxofusp - to me this is a sign they’re pivoting their plans for the drug which the slide deck confirms. Also interesting timing - JP Morgan conference with FM talking to the big wigs and now this latest commercial update drops? I am cautiously excited.
1 · Reply
Dipper2013
Dipper2013 Jan. 16 at 3:10 PM
$MDNAF ..and there we have it...please no more good news..it's killing the stock price🤣
1 · Reply
Latest News on MDNAF
No data available.
AuriniaBeach
AuriniaBeach Jan. 29 at 9:00 PM
$MDNAF New PRISM-11 post, announcing that David has entered into a professional licensing and collaboration agreement with Medicenna Therapeutics. https://davidbakke.substack.com/p/a-note-on-prism-11-medicenna-and
1 · Reply
Lytnup
Lytnup Jan. 25 at 6:14 PM
$MDNAF Sorry if it’s been posted already - but latest corporate presentation deck for January 2026 is uploaded @ the company website. 50 pages - some kind of record!!! https://ir.medicenna.com/static-files/c4bd4892-7ceb-4d59-b061-77ea834ec278
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jan. 24 at 7:42 PM
$MDNAF For what it’s worth, Zack’s yesterday changed their rating…from a hold rating to a strong-buy rating
2 · Reply
BigJon123
BigJon123 Jan. 22 at 10:36 PM
$MDNAF maybe someone knows something we don’t! Good news on the way?
0 · Reply
Vikingess
Vikingess Jan. 22 at 6:55 PM
$MDNAF What did I miss?
0 · Reply
Dipper2013
Dipper2013 Jan. 22 at 4:50 PM
$MDNAF I think we need bad news to get it to go up...🤣
0 · Reply
Biosectors
Biosectors Jan. 20 at 11:39 PM
$MDNAF Let’s hope some movement in volume and price next week up to conference week. Praying a buy out indication before or after the conference presentation. Take a look at OCUL data due soon a buy out candidate right now 11 plus I am expecting 28 to 35 range offer. Similarly URGN it went to 30 but back to 20 now and a good shot of a buy out 35 to 45 range but no timeline it’s derisked asset generating revenue. SLS another candidate with potential CHRS another one still struggling but expect to be bought out in 2027
0 · Reply
Witzorwitzout1
Witzorwitzout1 Jan. 16 at 11:29 PM
$MDNAF Medicenna (US OTC: MDNAF | CAD: MDNA) long update Medicenna released their 2026 outlook yesterday morning and I want to highlight something important: MDNA11 doesn’t need Keytruda to work. The headline numbers, 50% objective response rate in expansion cohorts, 42% in patients who already failed checkpoint inhibitors, those are monotherapy results. No Keytruda. No Opdivo. Just MDNA11 alone. Think about that. These are patients who tried the blockbuster immunotherapies and they stopped working. MDNA11 is rescuing responses where checkpoints have failed. That’s a big deal. Why this matters for the investment thesis: There are now multiple paths to value here. 1.Monotherapy salvage: Patient fails Keytruda, give MDNA11 alone. This is the registrational path they’re planning for melanoma. 2.Combination play Pair MDNA11 with Keytruda upfront to expand the responder population from ~30% to potentially 40-50%. 3.Neoadjuvant (NEO-CYT) MDNA11 + checkpoint before surgery in earlier-stage melanoma.
1 · Reply
BigJon123
BigJon123 Jan. 16 at 6:52 PM
$MDNAF i bought more before these presentations came out - there is too much potential here IMO. The biggest hurdle (and a major one) is the funding for their plans but I am hopeful that FM can rub big pharma the right way. Interestingly, they’ve dropped the MDNA55 title and have reverted back to bizaxofusp - to me this is a sign they’re pivoting their plans for the drug which the slide deck confirms. Also interesting timing - JP Morgan conference with FM talking to the big wigs and now this latest commercial update drops? I am cautiously excited.
1 · Reply
Dipper2013
Dipper2013 Jan. 16 at 3:10 PM
$MDNAF ..and there we have it...please no more good news..it's killing the stock price🤣
1 · Reply
Dipper2013
Dipper2013 Jan. 16 at 1:46 PM
$MDNAF all I see is a stock that has great news drop 50%>I'd hate to see what happens with bad news
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jan. 16 at 1:35 PM
$MDNAF Deck update https://ir.medicenna.com/static-files/c4bd4892-7ceb-4d59-b061-77ea834ec278
0 · Reply
Biosectors
Biosectors Jan. 16 at 1:23 AM
$MDNAF So confusing signals and path. Are we looking at 12 to 24 months or is the stage set for potential buy out down the road end of 2026 or mid 2027. Does this company has the resources and capital to run a big trial since mdna11 is still construed as good candidate but need more matured data by big pharma for a buy out possibility. 113 still infancy and BMS combo still 8 months away for any meaningful intermittent data read outs. Oh well it’s sink or swim probably and I will hold with hopes of a buy out in late 2026 or early 2027.
0 · Reply
Lytnup
Lytnup Jan. 15 at 12:53 PM
$MDNAF Happy Thursday!! https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-announces-key-program-updates-and-2026
2 · Reply
Biosectors
Biosectors Jan. 14 at 1:56 AM
$MDNAF Good news and exposure / publicity Having waited patiently for years I hope this small biotech with cutting edge science and approach be bought out by Merck or BMS or Roche in 2026 based on 113 NHP data , Italian trials with BMS drug and mature data of 11 with Keytruda. Partnership is an agonizing wait with bio bucks , upfront money blah blah milestones and so many riders. Value of partnership is not undermined but this small biotech will go no where with such grandiose pathways unless it’s a carrot to dangle in front of pharmas to seriously bid and buy out but not sure that route is valid.
2 · Reply
Lytnup
Lytnup Jan. 13 at 9:04 PM
$MDNAF Here’s to the New Year, and the MDNA team successfully partnering for the next phase of compound evaluations! https://www.linkedin.com/posts/medicenna-therapeutics-corp-_superkine-jpm2026-jpmhc26-activity-7416508280165801984-PoCV?utm_medium=ios_app&rcm=ACoAAAsnC8EBAcKQyUEEvVrkPzTEpnlOSa2bgnk&utm_source=social_share_send&utm_campaign=copy_link
0 · Reply
Biosectors
Biosectors Jan. 7 at 8:31 PM
$MDNAF 113 has a long way to go probably 2 years but this NHP data may lead to some good science and studies from a toxicity, treatment combos like MDNA11 etc. we need continuous update on ability trials till May/June so matured data gets noticed by Big guys and street. Good results from Italian trials and update by sponsor every 8 weeks will be icing on cake that can potentially make noise and dent in melanoma space which is already proved but with BMS drug combo it may open doors for buy out. Merck is a perfect fit with so Much data and a billion is chump change for Merck for the 11, 55 and platform itself with best in class superkines. 2 years ago Sanofi blew away 2.5 billion on a third class IL and shelved it, will they acquire this now ?
0 · Reply
Spartrap
Spartrap Jan. 7 at 3:40 PM
$MDNAF MDNA113 NHP data coming very soon 🤞🏻🤞🏻🤞🏻
0 · Reply
boomshiva
boomshiva Jan. 2 at 2:37 PM
$MDNAF Tax loss selling is done and new positions being re/established?
1 · Reply
Lytnup
Lytnup Jan. 1 at 4:46 PM
$MDNAF An interesting recap of MDNA55, and some possible / probable next steps. https://open.substack.com/pub/davidbakke/p/back-to-the-future-of-mdna55-when?r=10wt7d&utm_medium=ios Looking forward to February’s Drug Development Summit https://glioblastoma-drugdevelopment.com
0 · Reply
Lytnup
Lytnup Dec. 31 at 1:32 PM
$MDNAF Some ight reading for all MDNAs on the last trading day of the year….. https://open.substack.com/pub/davidbakke/p/immune-governance-part-2?r=10wt7d&utm_medium=ios Here’s to more clinical data & validation -
0 · Reply
Biosectors
Biosectors Dec. 29 at 1:50 AM
$MDNAF Funding I am hoping and praying more matured Ability data in June with mdna113 in the mix even though a long way to go plus the Italian melanoma trial results with mdna11 combo Will pave way for Merck or BMS to consider a buy out. I still feel it’s a good fit for Merck considering they are doing combo trials since 18 months or so. Feel very optimistic about a big pharma and street exposure in first half of 2026. Good luck to all longs and happy new year.
1 · Reply